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Abstract
Background: This study compared the level of advanced glycation end products (AGEs), N-(Carboxymethyl)lysine
(CML) and N-(Carboxyethyl)lysine (CEL), in patients with multiple sclerosis (MS) and healthy controls (HCs),
correlating these markers with clinical indicators of MS disease severity.
Methods: CML and CEL plasma levels were analyzed in 99 MS patients and 43 HCs by tandem mass spectrometry
(LC/MS/MS). Patients were stratified based on drug modifying therapies (DMTs) including interferon beta, glatiramer
acetate and natalizumab.
Results: The level of plasma CEL, but not CML, was significantly higher in DMT-naïve MS patients when compared
to HCs (P < 0.001). Among MS patients, 91% had higher than mean plasma CEL observed in HCs. DMTs reduced
CML and CEL plasma levels by approximately 13% and 40% respectively. CML and CEL plasma levels correlated
with the rate of MS clinical relapse.
Conclusion: Our results suggest that AGEs in general and CEL in particular could be useful biomarkers in MS
clinical practice. Longitudinal studies are warranted to determine any causal relationship between changes in
plasma level of AGEs and MS disease pathology. These studies will pave the way for use of AGE inhibitors and
AGE-breaking agents as new therapeutic modalities in MS.
Background
Advanced glycation end products (AGEs) are a hetero-
geneous class of compounds formed by nonenzymatic
glycation and oxidation of proteins and lipids via highly
reactive intermediates [1,2]. They have the potential to
interact with a specific receptor (RAGE), a member of
the immunoglobulin superfamily, initiating signaling
pathways that amplify inflammation and oxidative stress,
and thereby leading to cellular injury and death [3].
The level of AGEs increases both during physiological
aging [4] and in pathophysiological settings such as dia-
betes mellitus (DM) [5], rheumatoid arthritis (RA) [6]
and Alzheimer’s disease (AD) [7]. Accumulative data sug-
gest that AGEs may be increased in multiple sclerosis
(MS), an autoimmune disease of the CNS characterized
by inflammation, oxidative stress, and demyelination,
which leads to axonal injury and neurodegeneration [8].
This assumption is supported by studies showing an
increase in lipid peroxidation products in the CSF,
plasma, and brain of MS patients [9-11]. In addition, the
upregulation of the AGE receptor in oligodendrocytes,
the myelin-forming cells of the CNS, is a prerequisite
for the induction of oxidative damage leading to oligo-
dendrocyte death [12].
AGEs could contribute to neurodegeneration via multi-
ple pathways. By upregulating inflammatory cytokines and
reactive oxygen species, AGEs have the potential to induce
microglial activation [13]. Both oligodendrocytes death
and macroglial activation are early stages of lesion forma-
tion in MS [14]. In addition, AGEs could cause neuronal
cell death directly, independent of their effect on oligoden-
drocyte and microglial cells, since the addition of AGEs to
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increase in cell death [15], which could in turn be neutra-
lized by the addition of an AGE-specific antibody [15].
Iron deposition in the MS brain [16] could accelerate
AGE formation [17], contributing to an increase in blood
brain barrier permeability [18], an early and a critical
event in MS pathology [19]. Since RAGE expression is
positively regulated by AGEs [20], accelerated AGE pro-
duction could lead to sustained RAGE expression and
the amplification of inflammatory responses [21]. The
involvement of AGEs in MS pathology is further sup-
ported by a study showing a relationship between the
polymorphism of glyoxalase I, the gene encoding anti-
glycation defense, and MS susceptibility [22].
This study was intended to determine the plasma
levels of two well characterized AGEs, N-(Carboxy-
methyl)lysine (CML) and N-(Carboxyethyl)lysine (CEL),
in MS patients and healthy control subjects, and to
determine whether CML and CEL could be used as
serum markers of disease activity/severity through corre-
lation with clinical indicators of the MS disease includ-
ing the Extended Disability Status Scale (EDSS), MS
Severity Scale (MSSS), disease duration, and the rate of
clinical relapse in the two years preceding the time of
blood draw.
Methods
Population
Ninety-nine MS patients (71 females, 28 males, age 46.0
±1 1 . 5y e a r s )w e r er e c r u i t e df r o mt h eB a i r dM SC e n t e r ,
Department of Neurology, Jacobs Neurological Institute,
Buffalo, NY and from Kinkel Neurologic, Amherst, NY.
MS patients were compared with 43 healthy controls
(HCs) of similar age (32 females, 11 males) who were
recruited from the staff of the Neurology Department.
EDSS for MS patients ranged from 1 - 8.5 (mean 4.1 ±
2.2) with disease duration of 1 to 40 years. Patient popu-
lation included 65 relapsing-remitting (RR), 18 second-
ary progressive (SP), and 9 primary progressive (PP) MS
patients, along with 7 patients with clinically isolated
syndrome (CIS) suggestive of MS.
Among MS patients, 44 were treated with one of the
disease modifying therapies (DMTs) including interferon
beta, glatiramer acetate, and natalizumab; 55 were naïve
to these drugs. MS patients who received steroid treat-
ment within one month of blood draw, those who were
pregnant at the time of blood draw, and those with
other autoimmune diseases were excluded from the
study. In addition, patients with diabetes were excluded
due to the higher AGE plasma levels observed in these
patients [23,24]. Patients on statins were excluded from
the study due to the statins’ possible effect in lowering
AGE plasma levels [25].
Among the 99 MS patients, 29 were taking one of a
group of antihypertensive agents including beta-block-
ers, ace inhibitors and angiotensin receptor type 1
antagonist, while 25 of the 99 were on antidepressants.
Other common medication included antibiotics, provigil,
baclofen, albuterol, stool softeners, vitamins, and fish oil.
This study was approved by the Internal Review Board
of the University at Buffalo, Buffalo, NY. Patients signed
consent forms before their blood was drawn.
Reagents
All reagents including H2O, 6N HCl, trichloroacetic acid
(TCA), boric acid, sodium borohydride (NaBH4),a n d
nonafluoropentanoic acid (NFPA) were of analytical
grade and were obtained from Sigma. CML, CEL, D4-
CML, and D4-CEL were purchased from Dr. Herman
Ten Brink (VU Medical Center, Metabolic Laboratory,
Amsterdam, The Netherlands).
Measurements
Plasma samples were obtained, and were frozen within
15 minutes of blood draw at -80°C until assayed. Plasma
l e v e l so fC M La n dC E Lw e r em e a s u r e di nt h ep r o t e i n
fraction by stable-isotope dilution tandem mass spectro-
metry described by Teerlink, et al [ 2 6 ] .B r i e f l y ,p l a s m a
samples were treated with100 mM NaBH4 in 200 mM
borate buffer, pH 9.2 for 2 hours at room temperature.
Proteins were precipitated by 200 g/L TCA. After the
addition of 4.0 μMD 4-CML and 4.0 μMD 4-CEL, sam-
ples were hydrolyzed in 6N HCl at 110°C for 20 hours.
At completion of the hydrolysis reaction, samples were
blown dry under a stream of N2 gas at 85°C, then
diluted and neutralized with 5 mM NFPA, filtered
through a 0.45 μm-pore filter, and stored at -20°C. Cali-
bration standards were prepared by mixing 1:1: 8 ratio
of CML-CDL with D4-CML-D4-CEL and 5 mM NFPA
respectively.
LC/MS/MS analyses were performed on an API 3000
quadropole LC/MS/MS Mass Spectrometer (AB Sciex
Instruments) interfaced with an Agilent 1100 HPLC.
Mass spectra were acquired and processed with Analyst
1.4.2 software (AB Sciex Instruments). LC/MS/MS con-
ditions: samples were analyzed at 40°C by reversed
phase HPLC on a Waters Symmetry C18 column, 2.1 ×
150 mm, 5 μm. Mobile phase A was 5 mM NFPA in
water and mobile phase B was acetonitrile. Injection
volume was 20 μL with a flow rate of 220 μL/min. Com-
pounds were eluted with a linear gradient. From 0 to 1
min mobile phase B was at 10%; from 1 min to 12 min
mobile phase B was increased to 80%; after hold at 90%
B for 4 min; the percentage of B was reduced to initial
condition and hold for 4 min to bring the column to
equilibrium.
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spray source. API3000 was operated in positive mode
with the ion spray voltage at 4500 V; the decluster
potential was 21V, and focusing potential was 240 V.
The source temperature was 450°C. For CML and D4-
CML, the transition of m/z 205.1/84.0 and m/z 209.2/
88.0 were monitored; for CEL and for D4-CEL, the tran-
sition of m/z 219.0/84.0 and m/z 223.0/88.0 were moni-
tored. The calibration range for CML and CEL was
from 0.005 to 0.5 μmol/ml and was obtained by linear
regression of a plot of the analyte/internal standard
peak-area ratio vs. analyte concentration. The CML and
CEL were expressed as ng/ml.
Quality control tests
1. To prevent inter-assay variations, samples from both
MS patients and normal controls were continually
assayed in the same batch over 48 hours.
2. A pooled sample of MS patients and HCs was
assayed at different time points over the course of the
run to assure consistency in instrument performance.
3. Both 1:1diluted and non-diluted samples were
assayed to rule out any concentration effect on the beha-
vior of the studied compound during mass spectrometry.
4. Because of the prevalence of diabetes, and because
plasma levels of AGEs have been shown to be elevated
in diabetic subjects [23,24], plasma samples were ran-
domly selected from both MS and normal groups and
were assayed for HgA1c levels in order to rule out the
possibility of pre-diabetic conditions affecting CML and
CEL plasma levels. HgA1c plasma levels were measured
in the clinical laboratories of Buffalo General Hospital,
Buffalo, NY.
Statistics
All statistical analyses were performed using SPSS 14.0
for Windows (SPSS Institute, Chicago, IL, USA). Analy-
sis of variance (ANOVA) co-varied for age and gender
was used to test the significance of differences in plasma
CML and CEL between HCs, DMT-naïve MS patients
and MS patients on DMTs. ANOVA also examined the
differences in CML and CEL plasma levels among MS
patients at different disease stages. A simple t-test
assessed the differences in CML and CEL plasma levels
between clinically stable MS patients and MS patients in
clinical relapse, as well as differences in the percent of
HgA1c between MS patients and HCs. The relationship
among MS indicators of disease severity (EDSS, MSSS,
disease duration and the rate of clinical relapse two
years prior to blood draw), and CML and CEL plasma
levels was examined using a linear regression model. P
≤ 0.05 was considered significant.
Results
Quality control tests
The coefficient of variation among the pooled samples
was 2.0% for CML and 2.1% for CEL. The coefficient of
variation for diluted vs. non diluted samples was 4.6%
for CML and 5.7% for CEL. The percent HgA1c was
similar between MS patients (5.25 ± 0.1%) and HCs
(5.28 ± 0.1%) (p = 0.83), suggesting the absence of pre-
diabetic conditions in either MS patients or HCs.
Plasma levels of CML and CEL in MS patients and HCs
Table 1 presents CML and CEL plasma levels in 43 HCs
and 99 MS patients, stratified by gender and disease
stage, and the associated p-values. Due to the possible
effect of DMTs on CML and CEL plasma levels, all other
analyses were conducted in DMT-naïve MS patients. Fig-
ure 1A compares CML plasma levels in DMT-naïve MS
patients and HCs stratified by gender. CML plasma levels
were not different between MS patients (325.6 ± 26.8 ng/
ml) and HCs (309.5 ± 20 ng/ml) (p = 0.6). Among MS
patients, 25/55 (45.4%) had a higher level of plasma CML
when compared to the mean plasma level observed in
HCs. Gender stratification showed a higher CML plasma
level in HC males (379.7 ± 32 ng/ml) compared to HC
females (285.4 ± 23 ng/ml) (p = 0.03), while plasma CML
levels tended to be lower in male MS patients (283.1 ±
26.1 ng/ml) compared to females (339.7 ± 34.6 ng/ml)
(p = 0.3). These gender differences led to a lower CML
plasma level in male MS patients when compared to
male HCs (p = 0.02).
Figure 1B compares CEL plasma levels between DMT-
naïve MS patients and HCs stratified by gender. CEL
plasma levels were 122% higher in MS patients (291.7 ±
25 ng/ml) compared to that in HCs (128.8 ± 12 ng/ml)
(p < 0.001). CEL plasma levels were significantly higher
in HC males (178.4 ± 16 ng/ml) compared to HC
females (111.7 ± 14 ng/ml) (p = 0.02), and tended to be
lower in male MS patients (338.8 ± 72 ng/ml) compared
to females (276.1 ± 23 ng/ml) (p = 0.3). Approximately
91% (50/55) of MS patients had plasma CEL levels
above the mean observed in HCs.
Effects of DMTs on CML and CEL plasma levels
Figure 2A and Figure 2B respectively compares CML
and CEL plasma levels between DMT-naïve MS patients
(n = 55) and those patients on DMTs (n = 44). Patients’
stratification based on their DMT regimen showed
13.7% lower plasma CML in MS patients treated with
DMTs (280.9 ± 18 ng/ml) compared to patients naïve to
DMTs (325.6 ± 26.8 ng/ml) (p = 0.2) (Figure 2A). The
DMT regimen led to a reduction of 7% in plasma CML
levels in males (from 283.1 ± 26.1 ng/ml to 261.9 ± 24.8
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Groups Gender (n) CML (ng/ml) p value CEL (ng/ml) p value
HC M+F 43 309.5 ± 20(104-683) 128.8 ± 12(17-259)
M 11 379.7 ± 32(215-560) 178.4 ± 16(49-258)
F 32 285.4 ± 23(104-683) 0.03 111.7 ± 14(17-259) 0.02
MS M+F 99 306.4 ± 15 (117-911) 231.7 ± 15(29-781)
M 28 271.3 ± 17 (124-418) 237.8 ± 44(29-781)
F 71 319.2 ± 19 (117-911) 0.1 225.8 ± 15(34-651) 0.7
CIS M+F 7 336.5 ± 44(182-529) 218.4 ± 79(42-502)
M 4 317.2 ± 45 (182-372) 171.5 ± 106(45-488)
F 3 362.5 ± 95(197-529) 0.6 281.0 ± 132(42-502) 0.5
RRMS M+F 65 317.8 ± 17(140-869) 246.3 ± 20(47-781)
M 14 291.5 ± 21(145-418) 305.2 ± 68(47-781)
F 51 322.0 ± 22(140-869) 0.4 229.1 ± 17(49-651) 0.1
SPMS M+F 18 275.4 ± 52(117-911) 195.9 ± 33(29-460)
M 6 197.8 ± 28(124-271) 164.1 ± 73(29-327)
F 12 314.6 ± 75(117-911) 0.3 206.5 ± 39(34-460) 0.6
PPMS M+F 9 256.0 ± 20(151-362) 196.9 ± 28(53-362)
M 4 246.7 ± 46(151-362) 238 ± 71(115-362)
F 5 263.3 ± 22(217-334) 0.7 205 ± 10(176-225) 0.8
RRMS (clinically stable) M+F 49 302.9 ± 17(140-651) 263.4 ± 25(47-781)
M 13 293.6 ± 24(145-418) 302.6 ± 79(47-781)
F 36 308.5 ± 22(140-651) 0.7 245.1 ± 21(49-651) 0.3
RRMS (in clinical relapse) M+F 16 362.5 ± 42(158-869) 196.6 ± 22(74-442)
M 1 338.00 204.4
F 15 364.4 ± 45(158-869) 196.1 ± 24(75-442)
CML and CEL plasma levels in 43 HCs and 99 MS patients stratified by both disease stage and gender. The results are mean ± SEM and associated ranges.
P values are related to gender differences in CML and CEL plasma levels. P value ≤ 0.05 is statistically significant.
Figure 1 CML and CEL plasma levels in DMT-naïve MS patients and healthy controls: Comparison of plasma levels of CML (A) and CEL (B)
in DMT-naïve MS patients and HCs, stratified by gender. The results are means ± SEM. P value ≤ 0.05 is statistically significant. Abbreviations as
in Table 1 and DMT:disease modifying therapy.
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Page 4 of 8ng/ml, p = 0.7) and 11% in females (from 339.7 ± 34.6
ng/ml to 301.8 ± 26 ng/ml, p = 0.4).
Patients treated with DMTs had 40.5% lower plasma
CEL (173.4 ± 18 ng/ml) compared to DMT-naïve
patients (291.7 ± 25 ng/ml, p < 0.001) (Figure 2B). How-
ever, MS patients on DMTs still presented with a signif-
icantly higher CEL plasma level compared to HCs (p =
0.04). The percent reduction in CEL plasma levels due
to DMTs, was higher in males (57.4%, from 338.8 ±
72.1 ng/ml to 144.3 ± 29.6 ng/ml, p = 0.03) compared
to females (33.7%, from 276.1 ± 23.7 ng/ml to 183.0 ±
21.8 ng/ml, p = 0.007).
In addition, MS patients who were on antihypertensive
drugs had lower plasma CML (279.3 ± 24.1 ng/ml) com-
pared to patients who were not on this regimen (324.8 ±
26.0 ng/ml) (p = 0.4). Similarly, MS patients who were
on antihypertensive drugs had lower plasma CEL levels
(229.1 ± 57.0 ng/ml compared to patients who were not
on this regimen (287.7 ± 25.1 ng/ml) (p = 0.3).
Antidepressants were an additional common group of
drugs that MS patients were treated with at the time of
blood sampling. However, we did not observed any
effect of antidepressants on plasma levels of CML or
CEL (results are not shown).
CML and CEL plasma levels in MS patients at different
disease stages
Due to the lowering effects of DMTs, CML and CEL
plasma levels were compared in DMT-naïve, clinically
stable MS patients, at various disease stages. The level
of plasma CML was not different between RRMS
patients (n = 28) (314.3 ± 25.6 ng/ml) compared to
SPMS patients (n = 8) (229.7 ± 39.4 ng/ml), PPMS
patients (n = 7) (270.1 ± 27 ng/ml) and CIS patients (n
= 4) (276.7 ± 50 ng/ml) (ps >0.05) (Figure 3A). Simi-
larly, the level of plasma CEL was not different between
RRMS patients (319.0 ± 35 ng/ml) compared to SPMS
patients (276.2 ± 30.9 ng/ml) and CIS patients (269.4 ±
130 ng/ml) (Figure 3B), but CEL plasma level tended to
be lower in PPMS patients (229.8 ± 28 ng/ml) compared
to RRMS patients (p = 0.08)
CML and CEL plasma levels in clinically stable MS patients
and MS patients in clinical relapse
Since there was only one male MS patient who had clin-
ical relapse at the time of blood draw, we compared
clinically stable female RRMS patients (n = 25) with
female RRMS patients in clinical relapse (n = 7). CML
plasma levels tended to be higher in DMT-naïve MS
patients who were in relapse (429.8 ± 88.6 ng/ml) com-
pared to similar group of patients who were clinically
stable (306.0 ± 29.8 ng/ml) (p = 0.09). However, CEL
plasma levels were not different between patients in
clinical relapse (274.0 ± 59.1 ng/ml) compared to clini-
cally stable MS patients (260.8 ± 21.4 ng/ml) (p = 0.8).
Correlation between plasma CML and CEL and indicators
of MS disease severity
There was no correlation between age and plasma CML
or CEL levels in either MS patients or normal subjects.
When measured in DMT-naïve patients, CEL plasma
levels (R = 0.25, Rsqr = 0.06, Adj Rsqr = 0.05, p = 0.01)
correlated with the rate of clinical relapse, during the
two years before the time of blood sampling, more sig-
nificantly than CML plasma levels (R = 0.23, Rsqr =
0.05, Adj Rsqr = 0.04, p = 0.04). No significant correla-
tion between CML and CEL plasma levels, and EDSS
and MSS was observed.
Discussion
This study examined plasma levels of CML and CEL, two
well-characterized AGEs, in MS patients and HC
Figure 2 CML and CEL plasma levels in DMT-naïve MS patients and MS patients treated with DMTs. Comparison of Plasma levels of CML
(A) and CEL (B) in DMT-naïve MS patients and patients on DMTs, stratified by gender. The results are means ± SEM. P value ≤ 0.05 is statistically
significant. Abbreviations as in Table 1, and DMT:disease modifying therapy.
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diabetic conditions in the study population, we found sig-
nificantly higher plasma levels of CEL in MS patients
compared to HCs. CML plasma levels were not different
in MS patients compared to HCs, but similar to CEL,
CML plasma levels correlated with the rate of clinical
relapse, measured the two years before blood sampling,
suggesting that both CML and CEL may be involved in
MS pathology. This conclusion is further supported by
immunohistochemical studies in the authors’ laboratory
showing increased immunostaining of CML and its
receptor RAGE in postmortem hipocampi slides derived
from MS patients when compared to those from
HCs [27].
Since AGEs promote inflammation and oxidative
stress [28], higher levels of AGEs in MS patients suggest
higher inflammatory state, hence predisposing these
patients to a higher rate of yearly clinical relapse.
The increase in AGE plasma levels in MS patients
could be due to either leakage resulting from blood-
brain barrier dysfunction [29] or it can stem from the
activation of patients’ peripheral immune cells due to
chronic ongoing inflammation and oxidative stress [30].
CML and CEL have inflammatory effects via signaling
through the RAGE receptor [3]. Both agents are formed
through Maillard reaction, which combines reduced
sugars with the amino-acid lysine to form glycated
adducts called Amadori products. These byproducts can
then undergo further intramolecular rearrangement to
produce the two AGEs. However, in addition to glycoxi-
dation, lipid oxidation can also contribute to the forma-
tion of CML and CEL [31].
CML can be formed via multiple pathways including
the reactive intermediate glyoxal, but the primary path-
way for CEL formation is a nonenzymatic reaction
between the reactive intermediate methylglyoxal, formed
by protein glycoxidation, or enzymatic glycolysis with
lysine residues [32,33]. Both glyoxal [34] and methyl-
glyoxal [35] have been shown to be neurotoxic, but they
have been shown to induce cellular death via different
signaling pathways [36], suggesting that CML and CEL
may be involved in different aspects of MS pathology.
The other significant result of this study was the lower-
ing effect of DMTs on plasma AGEs. The level of plasma
C E Lw a sl o w e ri nM Sp a t i e n t so nD M T sa n di nH C s
compared to DMT-naïve patients. In addition, CEL
plasma levels were more significantly affected by DMTs
than CML plasma levels, and more significantly in male
patients than in females. It is known that men have a
more severe MS disease with usually a higher rate of dis-
ease progression. Future larger studies evaluating the
AGES plasma levels in relation to gender may shed a
light in understanding of disease heterogeneity leading to
a more specific individualized therapeutic interventions.
Despite the correlation between the plasma level of
AGEs and the rate of clinical relapse, and the notion
that clinical relapse represents a heightened inflamma-
tory status [37], one could not observe a significantly
higher plasma level of AGEs in patients during relapse
when compared to clinically stable MS patients.
Although our results regarding the effect of relapse on
plasma CML and CEL levels are not conclusive, due to a
small sample size of relapsing patients who were naïve to
DMTs (n = 7), one should note that AGE accumulation in
tissues is attributed to chronic ongoing inflammation.
Assuming that in average MS patients experience 1-2 clin-
ical relapses per year, with each lasting no more than two
weeks, relapse time does not last long enough for accumu-
lation of AGEs in the blood. The measurement of plasma
AGEs in the same patient both during clinical relapse and
during remission may give a better indication for the use-
fulness of AGEs as predictive markers of clinical relapse.
Our results with MS patients are consistent with ear-
lier in vitro [38] and animal [39] studies showing that
Figure 3 Plasma CML and CEL levels in DMT-naïve MS patients at various disease stages. Plasma CML (A) and CEL (B) at various disease
stages, in DMT-naïve, clinically stable MS patients. Results are means ± SEM for 4 CIS patients, 28 RRMS patients, 8 SPMS patients and 7 PPMS
patients. Abbreviations as in Table 1.
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ever, this is the first study reporting the effect of DMTs
on lowering plasma AGEs in MS patients. These results
suggest that DMTs may exert therapeutic effects in part
through modulation of AGEs. The higher level of AGEs
in MS can affect the expression of the RAGE receptor,
promoting downstream inflammatory and neurodegen-
erative processes [40]. Interestingly, these agents tend to
reduce CEL levels mainly in males, suggesting that gen-
der differences may be involved in the therapeutic
effects of DMTs [41,42].
Since AGEs are markers of inflammation and oxidative
stress, they are not specific to MS, but have been shown
to be upregulated in other neurodegenerative diseases
such as Alzheimer’s disease [43]. Furthermore, AGEs
have been shown to be involved in a number of demyeli-
nating diseases. AGE-modified peripheral nerve myelin is
susceptible to phagocytosis by macrophages contributing
to demyelination and peripheral neuropathy in diabetic
patients [44]. Furthermore, immunohistochemical studies
observed the upregulation of AGE CML in the neurons
and in microglia of spinal cord of patients suffering from
amyotrophic lateral sclerosis [45].
Although this study did not measure the level of total
lysine-containing proteins, the results of a two-dimen-
sional electrophoretic procedure did not observe differ-
ences in plasma proteins between MS patients and
normal control subjects [46].
Conclusion
Our results suggest that plasma AGEs may provide a
simple and novel diagnostic tool in MS. This is espe-
cially true with CEL levels, where 91% of patients were
identified as having higher than normal levels of AGEs.
Future studies with larger cohort will be needed to
assess AGEs usefulness as serum biomarkers in MS, and
whether these markers could supplement current moni-
toring strategies in clinical trials.
Assessment of AGE involvement in MS pathology will
pave the way for the introduction of AGE inhibitors or
AGE breaking agents in MS clinical practice. Phase II
clinical trial of the AGE breaker ALT-711 conducted in
93 individuals over the age of 50 with evidence of vascu-
lar stiffening showed reduction in arterial pulse pressure
and increase in large artery compliance [47]. AGE inhi-
bitors have been also suggested as promising neuropro-
tective strategies [48].
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